Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Opieka pielęgniarska nad pacjentem ze szpiczakiem mnogim, po autologicznym przeszczepieniu krwiotwórczych komórek macierzystych – studium przypadku.

100%
Kurek M. S., Tatara T., Patyk A.
Long-Term Care Nursing
|
2020
|
vol. 5
|
issue 2
147-157
EN
Introduction Multiple myeloma is one of the most common haematological cancer among adults. The main symptom of multiple myeloma is bone pain because of osteolysis, usually confused with osteoporosis. The basis method of treatment is chemotherapy with autologous hematopoietic stem cell transplantation. Aim The purpose of the work is case study of patient with diagnosed multiple myeloma and presentation of patient problems and nursing interventions in peri-transplant period Material and methods Information was collected by observation, interview and analysis of medical documentation of patient. Presented case show a 53 years old women, with multiple myeloma, who was treated by chemotherapy with autologous hematopoietic stem cell transplantation. Results One of the potential factors, which influence on development of cancer is lack of appropriate amount of dream, but in the literature we can find controversial information. Using ICNP® in practice, makes easier work of nurses. Conclusions Patients nursing care after autologous hematopoietic stem cell transplantation is difficult. As a result of treatment side effects, patients have a lot of problems. They require professional care and support.
PL
Wstęp Szpiczak mnogi (ang. multiple myeloma) stanowi jeden z najczęściej występujących nowotworów hematologicznych wśród dorosłych. Głównym objawem szpiczaka jest ból kości spowodowany osteolizą, zazwyczaj mylony z osteoporozą. Podstawową metodą leczenia jest chemioterapia wraz z autologicznym przeszczepieniem krwiotwórczych komórek macierzystych. Cel Celem pracy jest analiza przypadku pacjentki ze zdiagnozowanym szpiczakiem mnogim oraz przedstawienie problemów chorej i postępowania pielęgniarskiego w okresie okołotransplantacyjnym. Materiał i metody Informacje zebrano poprzez obserwację, wywiad i analizę dokumentacji medycznej pacjentki. Prezentowany przypadek opisuje kobietę w wieku 53 lat, ze szpiczakiem plazmocytowym, poddanej chemioterapii z autoprzeszczepieniem krwiotwórczych komórek macierzystych. Wyniki Jednym z potencjalnych czynników wpływających na rozwój nowotworu jest brak odpowiedniej ilości snu, jednak literaturze można odnaleźć kontrowersyjne informacje. Wnioski Opieka pielęgniarska nad pacjentem po autotransplantacji krwiotwórczych komórek macierzystych jest trudna. W wyniku wystąpienia działań niepożądanych leczenia, pacjenci mają wiele problemów. Wymagają profesjonalnej opieki i wsparcia. Stosowanie ICNP® w praktyce ułatwia pracę pielęgniarek.
2
Publication available in full text mode
Content available

SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR+DASABUVIR IN CHRONIC HEPATITIS C PATIENTS WITH HCV GENOTYPE 1 INFECTION

100%
Tatara T., Dąbrowska-Bender M., Staniszewska A., Duda-Zalewska A.
Acta Poloniae Pharmaceutica - Drug Research
|
2019
|
vol. 76
|
issue 4
613-620
EN
Introduction The assessment of the safety profile of ombitasvir/paritaprevir/ritonavir+dasabuvir in adult chronic hepatitis C patients with confirmed HCV genotype 1 presence. Material and method Evaluation of clinical safety based on the results of primary studies found in the systematic review. The following literature databases were searched: Medline, Embase, Cochrane Library and others. Results Finally two clinical trial met the inclusion criteria. The study included untreated patients (SAPPHIRE I) or patients after unsuccessful therapy (SAPPHIRE II), with genotype 1 infection. In patients without prior treatment the prevalence of the reported adverse events was in general statistically significantly greater in the group on therapy 3D+RBV compared to the placebo group. No statistically significant differences were observed in relation to the risk of serious adverse events or therapy discontinuance due to adverse events. In patients after unsuccessful therapy the prevalence of the reported adverse events was statistically significantly greater in the group on therapy 3D+RBV compared to the placebo group. During the 3D+RBV itching was statistically significantly more frequently reported in the placebo group. Compared to the other adverse events, no statistically significant differences were observed. Conclusions Interferon-free therapies provide a safe therapeutic option in the population of adult patients with chronic genotype 1 hepatitis C, both those untreated and after unsuccessful two-drug PegIFNα-based therapy, patients with HIV co-infection and patients after liver transplantation.
3
Publication available in full text mode
Content available

COMPARISON OF PERSONALIZED AND STANDARD PROPHYLAXIS BASED ON OCTOCOG ALFA IN PEDIATRIC PATIENTS WITH HEMOPHILIA A

88%
Tatara T., Dąbrowska-Bender M., Duda-Zalewska A., Staniszewska A., Kurek M.
Acta Poloniae Pharmaceutica - Drug Research
|
2020
|
vol. 77
|
issue 2
221-218
EN
Comparison of personalized and standard prophylaxis prevention therapies based on octocog alfa in pediatric patients with hemophilia A. Studies on a general population (adults and children) demonstrate a statistically significant advantage of personalized prevention therapy over standard prophylaxis prevention therapy in terms of annual bleeding rate (ABR) and annual joint bleeding rate (AJBR) while studies on a pediatric population included insufficiently large populations, however, their results demonstrate a numerical advantage of personalized approach over standard prevention strategy prophylaxis regimen.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.